Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00577590|
Recruitment Status : Completed
First Posted : December 20, 2007
Last Update Posted : February 9, 2018
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus, Type II||Drug: Lovaza Drug: Metformin Other: Placebo|
T2DM is the most common type of diabetes. In T2DM, the body does not properly process sugars and, as a result, there is an excess amount of sugar in the blood. Eventually, the high blood sugar levels can lead to heart disease, nerve damage, kidney problems, or blindness. Typical T2DM treatments target maintenance of blood sugar levels. Previous studies on T2DM have indicated that in people who have high amounts of fats in the blood, the body relies more heavily on fats than sugars as an energy source. This dependence on fats for energy has been shown to have a negative effect on heart function. There is reason to believe that lowering the levels of fats in the blood will enhance the ability of the heart and the whole body to efficiently use both fats and sugars as energy sources. This study will evaluate the effectiveness of treatment strategies that are designed to reach target levels of sugar and fat in the blood for treating people with T2DM.
Participation in this double-blind study will last between 4 and 6 months. First, participants will undergo a medical screening and medication adjustment period, expected to last 6 months. The medical screening, lasting about 1 hour, will involve completing a medical history, physical exam, pregnancy test if applicable, and blood test to measure various factors that contribute to diabetes control. Participants will also be asked permission to store 1 tablespoon of their blood for up to 10 years to be used in future studies concerning genetics and heart energy metabolism. During the medication adjustment period, study physicians will adjust the participants' medications, offer advice on diabetes education and nutrition, and record any side effects from the medications. For newly diagnosed T2DM participants, the study physician may recommend medication changes to assure a hemoglobin A1c (HgA1c) level of less than 7.5%. If participants have already achieved this level, they will be asked to continue present medications and to also begin taking the medication metformin for the 30 days before they undergo several imaging studies. Next, participants will complete routine tests that evaluate the pumping function of the heart, including an electrocardiogram (ECG) performed before and during exercise, a body composition study using a dual energy x-ray absorptiometry (DEXA) scan, and a magnetic resonance imaging (MRI) test. Each of these tests will last between 30 and 90 minutes.
After the qualifying tests, participants will return for the first of two separate imaging days that will include the same tests. The second imaging day will occur at the end of the medication period, approximately 2 months after the first imaging day. The first tests will be a whole body metabolism study and a heart metabolism imaging study, performed simultaneously. The whole body metabolism study will involve the injection of two tracers of metabolism, one for glucose and one for fatty acids. The heart metabolism imaging study will involve a positron-emission tomographic (PET) scan to take pictures of the heart and will include blood draws. The final imaging test will be a resting echocardiogram (ECHO) to measure heart function.
Following completion of the first day of imaging tests, participants will be randomly assigned to one of two possible treatment groups: Group A or B. In addition to continuing current medications, both groups will begin taking metformin daily. Group A will also take a pill of Lovaza daily, and Group B will take a matching placebo of Lovaza daily. Participants will be seen monthly for the next 4 months, during which study medication will be distributed and blood pressure, heart rate, weight, and any side effects, such as lower extremity swelling, will be measured. If there is a noticeable increase in swelling, study physicians may adjust medication dosages. During visits at Months 2 and 4, blood samples will be taken to measure liver and organ function and HgA1c. At the completion of the 4-month medication treatment, participants will undergo repeat imaging tests. If needed, participants will be offered the opportunity to attend one or more follow-up visits to re-establish a medication routine.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||146 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes|
|Study Start Date :||October 2003|
|Primary Completion Date :||August 2012|
|Study Completion Date :||September 2012|
Experimental: Metformin and Lovaza
Participants assigned to take metformin and Lovaza
Dosage of 4 g to be taken daily for 2 months
Other Name: Omega-3-acid ethyl ester compoundDrug: Metformin
Dosage of at least 1000 mg to be taken daily for 4 months
Other Name: Non-thiazolidinedione (TZD) oral agents
Placebo Comparator: Metformin and Placebo
Participants assigned to take metformin and placebo
Dosage of at least 1000 mg to be taken daily for 4 months
Other Name: Non-thiazolidinedione (TZD) oral agentsOther: Placebo
Placebo is taken along with Metformin
- Impact of lowering triglycerides in patients with T2DM; the effect of Lovaza on whole body and myocardial substrate metabolism and function [ Time Frame: Measured at Year 5 ]Taking Metformin with Placebo, Metformin with Rosiglitizone, and Metformin with Lovaza to determine the impact of lowering tryglycerides in patients with Type 2 Diabetes Mellitus
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00577590
|United States, Missouri|
|Washington University in St. Louis|
|Saint Louis, Missouri, United States, 63110|
|Principal Investigator:||Robert Gropler, MD||Washington University School of Medicine|